Sagimet Biosciences Inc. (SGMT)

Market Cap	119.44M
Revenue (ttm)	n/a
Net Income (ttm)	-45.57M
Shares Out	32.20M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,266
Open	3.760
Previous Close	3.760
Day's Range	3.625 - 3.780
52-Week Range	2.390 - 7.380
Beta	n/a
Analysts	Strong Buy
Price Target	25.67 (+591.91%)
Earnings Date	Mar 12, 2025

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMT
• Website: https://www.sagimet.com

Analyst Forecast

According to 6 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price forecast is $25.67, which is an increase of 591.91% from the latest price.

Price Target

$25.67

(591.91% upside)

Analyst Consensus: Strong Buy